|
| 22 May 2023 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that the Trust which manages the Share Incentive Plan ("SIP"), previously referred to as the Deferred Share Bonus Plan ("DSB"), on behalf of the employees of AMS has purchased ordinary shares of 5 pence each ("Ordinary Shares"), at a share price of 251.07p on behalf of Chris Meredith and Eddie Johnson, who are both Directors/PDMRs, as part of the SIP and, under the terms of the SIP, these shares will be held in trust on their behalf.
Following these transactions the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:
| Director/PDMR | Date purchased | Shares purchased (through SIP) | Resultant holding | % of issued share capital |
| Chris Meredith Chief Executive Officer | 18 May 2023 | 13,859 | 1,774,021 | 0.82% |
| Eddie Johnson Chief Financial Officer | 18 May 2023 | 19,968 | 104,277 | 0.05% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name: Chris Meredith | ||||
2. | Reason for the notification | ||||
| a) | Position/status: Chief Executive Officer | ||||
| b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name: Advanced Medical Solutions Group plc | ||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
| b) | Nature of the transactions: · Purchase of Ordinary Shares as part of the Share Incentive Plan on 18 May 2023 | ||||
| c) | Price(s) and volume(s):
| ||||
| d) | Aggregated information: Aggregated volume: n/a Aggregated price: n/a | ||||
| e) | Date of the transaction: 18/05/2023 | ||||
| f) | Place of the transaction: London Stock Exchange (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name: Eddie Johnson | ||||
2. | Reason for the notification | ||||
| a) | Position/status: Chief Financial Officer | ||||
| b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name: Advanced Medical Solutions Group plc | ||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
| b) | Nature of the transactions: · Purchase of Ordinary Shares as part of the Share Incentive Plan on 18 May 2023 | ||||
| c) | Price(s) and volume(s):
| ||||
| d) | Aggregated information: Aggregated volume: n/a Aggregated price: n/a | ||||
| e) | Date of the transaction: 18/05/2023 | ||||
| f) | Place of the transaction: London Stock Exchange (XLON) |
- Ends -
For further information, please visit www.admedsol.com or contact:
| Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
| Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations | |
| |
|
| Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
| Matthew Neal / Lucy Featherstone | AMS@consilium-comms.com |
| | |
| Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
| Gary Clarence / David Anderson | |
| | |
| HSBC Bank PLC (Broker) | Tel: 44 (0) 20 7991 8888 |
| Sam McLennan / Joe Weaving / Stephanie Cornish | |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.